New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
November 4, 2024
November 4, 2024
Participation in Leading Investor Conferences
October 28, 2024
October 28, 2024
New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI
September 23, 2024
September 23, 2024
New Treatment Insights into Switching to UZEDY® from Perseris®
September 23, 2024
September 23, 2024
Reporting of the 2024 Annual General Meeting
September 13, 2024
September 13, 2024
Olanzapine LAI: No PDSS Observed After Completion of c.99% of the Targeted Injections for Submission
September 5, 2024
September 5, 2024
Progress in the Development of the Products Portfolio and the R&D Pipeline
September 3, 2024
September 3, 2024
Participation terms in the Combined General Meeting
August 26, 2024
August 26, 2024
Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
July 31, 2024
Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting
